Table 2 Cardiovascular outcomes occurring after a first within-trial non-fatal myocardial infarction in those randomized previously to sitagliptin or placebo treatment (intention-to-treat analysis)
|  | Sitagliptin n = 289 | Placebo n = 302 | Unadjusted hazard ratio (95% CI) | P-value | Adjusted hazard ratio (95% CI) | P-value | ||
|---|---|---|---|---|---|---|---|---|
No. (%) | Events per 100 patient-years | No. (%) | Events per 100 patient-years | |||||
Cardiovascular death or hospitalization for heart failure | 58 (20.1) | 13.9 | 50 (16.6) | 11.7 | 1.21 (0.83–1.77) | 0.32 | 1.23 (0.83–1.82) | 0.31 |
Cardiovascular death | 34 (11.8) | 7.6 | 32 (10.6) | 7.1 | 1.11 (0.68–1.81) | 0.67 | 1.12 (0.67–1.86) | 0.67 |
Hospitalization for heart failure | 31 (10.7) | 7.5 | 26 (8.6) | 6.1 | 1.26 (0.75–2.12) | 0.39 | 1.40 (0.80–2.42) | 0.23 |
New onset heart failure | 19 (6.6) | 4.3 | 17 (5.6) | 3.8 | 1.25 (0.64–2.44) | 0.51 | 1.49 (0.72–3.09) | 0.28 |
Cardiovascular death, hospital admission for heart failure, new heart failure, acute myocardial infarction, stroke or new-onset atrial fibrillation | 108 (37.4) | 33.0 | 100 (33.1) | 28.4 | 1.16 (0.89–1.53) | 0.27 | 1.21 (0.91–1.60) | 0.20 |
Further acute myocardial infarction | 54 (18.7) | 7.4 | 55 (18.2) | 7.1 | 1.01 (0.69–1.48) | 0.95 | 0.99 (0.67–1.46) | 0.95 |
All-cause death | 50 (17.3) | 11.0 | 37 (12.3) | 8.1 | 1.40 (0.92–2.15) | 0.12 | 1.41 (0.90–2.21) | 0.13 |